Interestingly, Ali and colleagues investigated different combinatorial therapies, considering CSF-1R, PD-1 and other targets, in glioblastoma and highlighted the importance of the therapy-induced time-dependent changes in TME cells (86). The gene discussed is CSF1R; the disease is glioblastoma.